Acarbose vs Metformin Comparison - Drugs.com
Compare Acarbose vs Metformin head-to-head with other drugs for uses, ratings, cost, side effects and interactions.
Cardiovascular Risk Associated With Acarbose Versus Metformin …
Mar 1, 2015 · Metformin is the first-line oral therapy for type 2 diabetes with proven benefits against cardiovascular risk. Recent evidence suggested that acarbose might be similar to metformin in glucose-lowering efficacy and cardiovascular risk reduction.
Acarbose compared with metformin as initial therapy in patients …
Oct 18, 2013 · This study provides evidence that acarbose is similar to metformin in efficacy, and is therefore a viable choice for initial therapy in Chinese patients newly diagnosed with type 2 diabetes.
Comparison of Glucose Lowering Effect of Metformin and Acarbose …
In direct comparison (8 trials), metformin reduced glycosylated hemoglobin (HbA 1c) by 0.06% more than acarbose, with no significant difference (WMD,-0.06%; 95% CI, -0.32% to 0.20%).
Metformin combined with acarbose vs. single medicine in the …
Meta-analysis revealed that compared with metformin monotherapy, combined therapy was significantly more efficacious regarding indexes including the total effective rate, fasting blood glucose (FBG), blood glucose levels at two post-prandial …
Acarbose Vs. Metformin: Drug Comparison | Take Care by Hers
Nov 4, 2024 · Research different treatment options with hers' side-by-side summaries of acarbose vs. metformin to compare approved uses, side effects, interactions, and more.
Cardiovascular risk associated with acarbose versus metformin …
Recent evidence suggested that acarbose might be similar to metformin in glucose-lowering efficacy and cardiovascular risk reduction. Therefore, international guidelines have suggested the use of acarbose as alternative first-line antidiabetic therapy.
Comparison of acarbose and metformin therapy in newly
Twenty-four weeks of therapy with acarbose and metformin induced similar reductions in HbA1c and body weight, but acarbose showed superior efficacy in improving islet α-cell function compared with metformin in overweight/obese patients with newly diagnosed T2DM.
Acarbose plus metformin fixed-dose combination outperforms acarbose ...
Compared with acarbose monotherapy, acarbose/metformin FDC has superior antihyperglycaemic efficacy, brings proportionally more T2D patients to HbA1c goal, and further reduces bodyweight. Acarbose/metformin FDC is well-tolerated without significant risk of hypoglycaemia and is a potentially advantag …
Acarbose - StatPearls - NCBI Bookshelf
Sep 1, 2020 · Compared to metformin therapy, the acarbose therapy group showed a statistically significant decrease in low-density lipoprotein (calculated), triglycerides, and total cholesterol. Acarbose use also led to a statistically significant reduction in regular insulin use. [3] Prediabetes. Acarbose is not FDA-approved for the treatment of prediabetes.
- Some results have been removed